Evinacumab Monoclonal Antibody to Reduce the Chance of Cardiovascular Diseases in Patients

Evinacumab Monoclonal Antibody to Reduce the Chance of Cardiovascular Diseases in Patients

Release Date: 13-Nov-2020



High cholesterol is known to be very unhealthy is present in high amount in a body. Also, increase in the amount of LDL is considered to be one of the most important markers of heart diseases. Therefore, most of the drugs that are developed for cholesterol targets reduction in the overall LDL cholesterol. The disease associated with cholesterol leads to the development of hypercholesterolemia which prematurely leads to atherosclerotic cardiovascular disease (ACVD). Therefore, the primary goal of the researchers is to prevent the onset of atherosclerotic cardiovascular disease and provide the patients with healthy lifestyle.

 

A group of researchers suggest that an investigational drug called as evinacumab is supposed to be effective in controlling the levels of LDL in the patients suffering from familial hypercholesterolemia. The base of the study is that familial hypercholesterolemia is linked with genetic variations or mutations leading to the impaired receptor activity of LDL and some of the other growth factors called as angiopoietin-like 3 (ANGPTL3). The investigational drug Evinacumab is a monoclonal antibody which is supposed to show its activity against ANGPTL3.

 

The clinical research study included 65 patients having familiar hypercholesterolemia with the investigational drug. After the continuous administration of the drug into the patients, there was a gradual reduction in the level of LDL cholesterol i.e. about 47.1%, whereas the placebo group only received 1.9% decrease in the level of LDL. The researchers came to a conclusion that the investigational drug developed by them was able to lower the level of LDL cholesterol and thus reducing the risk of development of any more cardiovascular diseases in the patients.

Need custom market research solution? We can help you with that too.